GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Pretax Margin %

Apollon Formularies (AQSE:APOL) Pretax Margin % : -1,591.67% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Apollon Formularies's Pre-Tax Income for the six months ended in Jun. 2023 was £-0.76 Mil. Apollon Formularies's Revenue for the six months ended in Jun. 2023 was £0.05 Mil. Therefore, Apollon Formularies's pretax margin for the quarter that ended in Jun. 2023 was -1,591.67%.

The historical rank and industry rank for Apollon Formularies's Pretax Margin % or its related term are showing as below:

AQSE:APOL' s Pretax Margin % Range Over the Past 10 Years
Min: -41100   Med: -745.92   Max: -1.22
Current: -1591.67


AQSE:APOL's Pretax Margin % is ranked worse than
96.47% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 4.27 vs AQSE:APOL: -1591.67

Apollon Formularies Pretax Margin % Historical Data

The historical data trend for Apollon Formularies's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Pretax Margin % Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.22 -14.22 - - -1,278.28

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -421.72 -128.48 -1,591.67

Competitive Comparison of Apollon Formularies's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Pretax Margin % falls into.



Apollon Formularies Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Apollon Formularies's Pretax Margin for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-2.531/0.198
=-1,278.28 %

Apollon Formularies's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-0.764/0.048
=-1,591.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Apollon Formularies Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013